JP2009512708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512708A5 JP2009512708A5 JP2008536806A JP2008536806A JP2009512708A5 JP 2009512708 A5 JP2009512708 A5 JP 2009512708A5 JP 2008536806 A JP2008536806 A JP 2008536806A JP 2008536806 A JP2008536806 A JP 2008536806A JP 2009512708 A5 JP2009512708 A5 JP 2009512708A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- laquinimod sodium
- sodium
- laquinimod
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- GKWPCEFFIHSJOE-UHFFFAOYSA-N Laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 15
- 229960004577 laquinimod Drugs 0.000 claims 15
- 239000000243 solution Substances 0.000 claims 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 239000007864 aqueous solution Substances 0.000 claims 6
- 239000012296 anti-solvent Substances 0.000 claims 4
- 229910001385 heavy metal Inorganic materials 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 229910052804 chromium Inorganic materials 0.000 claims 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 2
- 239000011651 chromium Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 229910052759 nickel Inorganic materials 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Claims (19)
- 結晶性のラキニモドナトリウム粒子の混合物であって、
i) 総体積量の10%以上のラキニモドナトリウム粒子が40ミクロンをこえるサイズを有する、または
ii) 少なくとも0.4 g/mlのタップ密度を有する、または
iii) 少なくとも0.2 g/mLの容積密度を有する、または
iv) ラキニモドナトリウムの総量に基づいて計算される2 ppm以下の重金属を有する混合物。 - 少なくとも0.4 g/mLのタップ密度を有する請求項1に記載の混合物。
- 少なくとも0.2 g/mLの容積密度を有する請求項1に記載の混合物。
- 当該混合物中にラキニモドナトリウムの総量に基づいて計算される2 ppm以下の重金属を有する請求項1に記載の混合物。
- 少なくとも0.2 g/mLの容積密度、および当該混合物中にラキニモドナトリウムの総量に基づいて計算される2 ppm以下の重金属を有する請求項2に記載の混合物。
- 請求項1〜5の何れか一項に記載の混合物であって、総体積量の50%以上のラキニモドナトリウム粒子は、15ミクロンをこえるサイズを有する混合物。
- 少なくとも0.5 g/mLのタップ密度、少なくとも0.3 g/mLの容積密度、および/または0.7 g/mL未満のタップ密度を有する請求項1〜6の何れか一項に記載の混合物。
- 前記重金属が鉄、ニッケルまたはクロムである、請求項1〜7の何れか一項に記載の混合物。
- 2 ppm以下の鉄、0.2 ppm以下のニッケル、および/または0.3 ppm以下のクロムを含む、請求項8に記載の混合物。
- 請求項1〜9の何れか一項に記載の混合物と薬学的に許容される担体とを含む薬学的組成物。
- 錠剤またはカプセル剤の形態の請求項10に記載の薬学的組成物。
- ラキニモドナトリウムの再結晶化の方法であって、以下を備える方法:
a) ラキニモドナトリウムを水に溶解して水溶液を形成することと;
b) 前記水溶液を濃縮して濃縮溶液を形成することと;
c) 水混和性の貧溶媒を前記濃縮溶液に添加してラキニモドナトリウム結晶を形成することと;
d) 前記ラキニモドナトリウム結晶を単離すること。 - さらに工程aa)を工程a)後且つ工程b)前に含み、前記工程aa)は前記水溶液を濾過して固形の不純物を除去することを備える、請求項12に記載の方法。
- 請求項12または13に記載の方法であって、
i) 工程a)は、前記水溶液を40〜80℃の温度に加温することにより行われる、または
ii) 工程c)に続いて当該溶液が10℃未満の温度まで冷却される、または
iii) 工程b)に続いて当該濃縮溶液がラキニモドナトリウムでシーディングされる、または
i)、ii)、およびiii)の任意の組み合わせ、
である方法。 - 請求項12〜14の何れか一項に記載の方法であって:
i) 前記濃縮溶液は、ラキニモドナトリウムのグラムあたり1〜4ミリリットル、好ましくは1〜2ミリリットルの水を含む、または
ii) 前記貧溶媒は、エタノール、イソプロパノール、およびアセトンからなる群の一つであるか又は一つ以上の混合物である、または
iii) 前記貧溶媒は、ラキニモドナトリウムのグラムあたり3および15ミリリットルの間の量で添加される、または
i)、ii)、およびiii)の任意の組み合わせ、
である方法。 - 請求項12〜15の何れか一項に記載の方法によって調製されたラキニモドナトリウムの混合物。
- 3-6 μmのd(0.1)、11-18 μmのd(0.5)、および/または25-45 μmのd(0.9)を有する、請求項16に記載の混合物。
- 請求項10または11に記載の薬学的組成物を作出するための方法であって、以下を備える方法:
a) ラキニモドナトリウムのバッチを取得することと;
b) 不溶物が工程a)のバッチに存在するかどうかを、前記バッチからのサンプルを脱イオン水中、室温で、少なくとも110 mgのサンプルに対し1.0 mlの水の比で混合し、及び生じた混合物を不溶物の存在に関して検査することにより決定することと;
c) 工程b)において不溶物がラキニモド製剤の安定性に有害な効果を生じることが判明している規定量未満で存在すると決定された場合に、工程a)のバッチを少なくとも一つの薬学的に許容される担体と混合すること。 - 請求項18に記載の方法であって、工程b)の混合物における不溶物が規定量未満で存在しないと決定された場合に、前記方法は更に以下を備える方法:
d) 工程a)のバッチを水に溶解して水溶液を形成することと;
e) 工程d)の水溶液を濾過して不溶物の量を規定量未満に減少させることと;
f) 工程e)の水溶液を濃縮して濃縮溶液を形成することと;
g) 水混和性の貧溶媒を工程f)の濃縮溶液に添加してラキニモドナトリウム結晶を形成することと;
h) 工程g)のラキニモドナトリウム結晶を単離すること。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72865705P | 2005-10-19 | 2005-10-19 | |
US60/728,657 | 2005-10-19 | ||
PCT/US2006/040925 WO2007047863A2 (en) | 2005-10-19 | 2006-10-18 | Crystals of laquinimod sodium, and process for the manufacture thereof |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012277069A Division JP2013100299A (ja) | 2005-10-19 | 2012-12-19 | ラキニモドナトリウムの結晶、及びその製造方法 |
JP2015152209A Division JP2016020353A (ja) | 2005-10-19 | 2015-07-31 | ラキニモドナトリウムの結晶,及びその製造方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009512708A JP2009512708A (ja) | 2009-03-26 |
JP2009512708A5 true JP2009512708A5 (ja) | 2012-03-08 |
JP5832716B2 JP5832716B2 (ja) | 2015-12-16 |
Family
ID=37963287
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008536806A Expired - Fee Related JP5832716B2 (ja) | 2005-10-19 | 2006-10-18 | ラキニモドナトリウムの結晶,及びその製造方法 |
JP2012277069A Withdrawn JP2013100299A (ja) | 2005-10-19 | 2012-12-19 | ラキニモドナトリウムの結晶、及びその製造方法 |
JP2015152209A Pending JP2016020353A (ja) | 2005-10-19 | 2015-07-31 | ラキニモドナトリウムの結晶,及びその製造方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012277069A Withdrawn JP2013100299A (ja) | 2005-10-19 | 2012-12-19 | ラキニモドナトリウムの結晶、及びその製造方法 |
JP2015152209A Pending JP2016020353A (ja) | 2005-10-19 | 2015-07-31 | ラキニモドナトリウムの結晶,及びその製造方法 |
Country Status (24)
Country | Link |
---|---|
US (4) | US7884208B2 (ja) |
EP (2) | EP1937642B1 (ja) |
JP (3) | JP5832716B2 (ja) |
KR (1) | KR101440982B1 (ja) |
CN (3) | CN107176923A (ja) |
AR (1) | AR056708A1 (ja) |
AU (1) | AU2006304672B2 (ja) |
BR (1) | BRPI0617477A2 (ja) |
CA (1) | CA2625287C (ja) |
DK (1) | DK1937642T3 (ja) |
ES (1) | ES2523762T3 (ja) |
HK (1) | HK1117160A1 (ja) |
HR (1) | HRP20141160T1 (ja) |
IL (1) | IL190137A (ja) |
NZ (2) | NZ567088A (ja) |
PL (1) | PL1937642T3 (ja) |
PT (1) | PT1937642E (ja) |
RS (1) | RS53666B1 (ja) |
RU (1) | RU2415841C2 (ja) |
SG (1) | SG10201508623RA (ja) |
SI (1) | SI1937642T1 (ja) |
UA (1) | UA92761C2 (ja) |
WO (1) | WO2007047863A2 (ja) |
ZA (1) | ZA200803527B (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
NZ567088A (en) * | 2005-10-19 | 2012-06-29 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
KR101495327B1 (ko) * | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
US8354428B2 (en) | 2008-07-01 | 2013-01-15 | Actavis Group Ptc Ehf | Solid state forms of laquinimod and its sodium salt |
WO2010028015A2 (en) * | 2008-09-03 | 2010-03-11 | Auspex Pharmaceuticals, Inc | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
WO2010070449A2 (en) | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
RS54328B1 (en) | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS |
MX2012001333A (es) * | 2009-07-30 | 2012-06-01 | Teva Pharma | Tratamiento de la enfermedad de crohn con la laquinimod. |
EP3064206B1 (en) * | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
NZ602512A (en) * | 2010-03-03 | 2014-07-25 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
EA201290837A1 (ru) | 2010-03-03 | 2013-05-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение волчаночного нефрита с применением лаквинимода |
AU2011223697B2 (en) * | 2010-03-03 | 2016-07-14 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
CN102985090B (zh) | 2010-07-09 | 2014-11-26 | 泰华制药工业有限公司 | 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途 |
WO2012006538A1 (en) * | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
EP2642855A4 (en) | 2010-11-28 | 2014-05-28 | Mapi Pharma Ltd | INTERMEDIATE COMPOUNDS AND METHOD FOR THE PREPARATION OF CHINOLIN DERIVATIVES SUCH AS LAQUINIMOD SODIUM |
BR112014008731A2 (pt) | 2011-10-12 | 2017-04-25 | Teva Pharma | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode |
JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗TNEα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
KR20140138725A (ko) | 2012-02-16 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도 |
US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
CN103626701A (zh) * | 2012-08-28 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉衍生物的方法 |
CN103626702A (zh) * | 2012-08-30 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉酮衍生物的方法 |
EP2894619A4 (en) | 2012-09-03 | 2016-03-16 | Toyota Motor Co Ltd | DEVICE AND METHOD FOR COLLISION DETERMINATION |
MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
WO2014152009A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
NZ630427A (en) * | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
MX2021001169A (es) | 2013-11-15 | 2023-02-10 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. |
EP3137092A4 (en) | 2014-04-29 | 2017-10-11 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US613574A (en) * | 1898-11-01 | Feed-regulator | ||
US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
CH687615A5 (de) | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
CN1127931C (zh) | 1997-09-19 | 2003-11-19 | 克斯克管理公司 | 便携式玩耍场场地支撑骨架 |
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
PT1187601E (pt) | 1999-06-07 | 2005-11-30 | Altana Pharma Ag | Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido |
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
PL199781B1 (pl) | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
EP1386926A1 (en) | 2002-07-29 | 2004-02-04 | Bioxtal | Methods for producing labelled recombinant polypeptides and uses thereof |
ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20040253305A1 (en) | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
EP1694308A1 (en) | 2003-10-30 | 2006-08-30 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
NZ567088A (en) * | 2005-10-19 | 2012-06-29 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
KR101495327B1 (ko) | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
US8354428B2 (en) | 2008-07-01 | 2013-01-15 | Actavis Group Ptc Ehf | Solid state forms of laquinimod and its sodium salt |
WO2010028015A2 (en) * | 2008-09-03 | 2010-03-11 | Auspex Pharmaceuticals, Inc | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
RS54328B1 (en) | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS |
MX2012001333A (es) | 2009-07-30 | 2012-06-01 | Teva Pharma | Tratamiento de la enfermedad de crohn con la laquinimod. |
EP3064206B1 (en) | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
EA201290837A1 (ru) | 2010-03-03 | 2013-05-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение волчаночного нефрита с применением лаквинимода |
AU2011223697B2 (en) | 2010-03-03 | 2016-07-14 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
NZ602512A (en) * | 2010-03-03 | 2014-07-25 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
WO2012006538A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
CN102985090B (zh) | 2010-07-09 | 2014-11-26 | 泰华制药工业有限公司 | 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途 |
US20120055072A1 (en) * | 2010-09-08 | 2012-03-08 | Rankin Sammy D | Directional guide for fishing lures |
CA2820586A1 (en) * | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
-
2006
- 2006-10-18 NZ NZ567088A patent/NZ567088A/en unknown
- 2006-10-18 CN CN201710533188.XA patent/CN107176923A/zh active Pending
- 2006-10-18 JP JP2008536806A patent/JP5832716B2/ja not_active Expired - Fee Related
- 2006-10-18 RS RS20140629A patent/RS53666B1/en unknown
- 2006-10-18 US US11/583,282 patent/US7884208B2/en not_active Expired - Fee Related
- 2006-10-18 RU RU2008119456/04A patent/RU2415841C2/ru not_active IP Right Cessation
- 2006-10-18 EP EP06826297.1A patent/EP1937642B1/en active Active
- 2006-10-18 SG SG10201508623RA patent/SG10201508623RA/en unknown
- 2006-10-18 CA CA2625287A patent/CA2625287C/en not_active Expired - Fee Related
- 2006-10-18 KR KR1020087011727A patent/KR101440982B1/ko not_active IP Right Cessation
- 2006-10-18 CN CN200680039201.6A patent/CN101291911B/zh not_active Expired - Fee Related
- 2006-10-18 PL PL06826297T patent/PL1937642T3/pl unknown
- 2006-10-18 PT PT68262971T patent/PT1937642E/pt unknown
- 2006-10-18 SI SI200631860T patent/SI1937642T1/sl unknown
- 2006-10-18 DK DK06826297.1T patent/DK1937642T3/en active
- 2006-10-18 ZA ZA200803527A patent/ZA200803527B/xx unknown
- 2006-10-18 UA UAA200806003A patent/UA92761C2/ru unknown
- 2006-10-18 EP EP13153698.9A patent/EP2687512A1/en not_active Withdrawn
- 2006-10-18 ES ES06826297.1T patent/ES2523762T3/es active Active
- 2006-10-18 WO PCT/US2006/040925 patent/WO2007047863A2/en active Application Filing
- 2006-10-18 BR BRPI0617477-9A patent/BRPI0617477A2/pt not_active Application Discontinuation
- 2006-10-18 CN CN2013102471796A patent/CN103333107A/zh active Pending
- 2006-10-18 NZ NZ592897A patent/NZ592897A/xx unknown
- 2006-10-18 AU AU2006304672A patent/AU2006304672B2/en not_active Ceased
- 2006-10-19 AR ARP060104574A patent/AR056708A1/es unknown
-
2008
- 2008-03-13 IL IL190137A patent/IL190137A/en not_active IP Right Cessation
- 2008-11-03 HK HK08112048.9A patent/HK1117160A1/xx not_active IP Right Cessation
-
2011
- 2011-01-21 US US13/011,233 patent/US8647646B2/en not_active Expired - Fee Related
- 2011-01-21 US US13/011,187 patent/US8673322B2/en not_active Expired - Fee Related
-
2012
- 2012-12-19 JP JP2012277069A patent/JP2013100299A/ja not_active Withdrawn
-
2014
- 2014-02-20 US US14/185,470 patent/US20140171647A1/en not_active Abandoned
- 2014-11-28 HR HRP20141160TT patent/HRP20141160T1/hr unknown
-
2015
- 2015-07-31 JP JP2015152209A patent/JP2016020353A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009512708A5 (ja) | ||
HRP20141160T1 (hr) | Kristali natrijevog lakvinimoda i postupak za njihovu proizvodnju | |
AU2005210174B2 (en) | New compositions containing quinoline compounds | |
US5980942A (en) | Zero-order sustained release matrix tablet formulations of carbamazepine | |
JP2008501802A5 (ja) | ||
CN106279121B (zh) | 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途 | |
JP2008531614A5 (ja) | ||
JPH02268178A (ja) | 3―ホルミルアミノ―7―メチルスルホニルアミノ―6―フェノキシ―4h―1―ベンゾピラン―4―オンまたはその塩を含有する抗炎症製剤 | |
BRPI0612295A2 (pt) | base livre de escitaloproma, composição farmacêutica, processo para a fabricação de base livre de escitaloprama ou um sal da mesma, base cristalina de escitaloprama ou um sal de oxalato de escitaloprama, processos para a fabricação de um sal de escitaloprama e para a redução da quantidade de escitaloprama, n-óxido em base livre de escitaloprama ou um sal da mesma, tablete orodispersável, e, método de fabricação de um tablete orodispersável | |
CN105985394B (zh) | 一种索非布韦新晶型及其制备方法 | |
KR20160036108A (ko) | 알킬화 종으로의 노출과 관련된 상해를 치료하는 방법 | |
Raybin | A new color reaction with sucrose | |
TW201041574A (en) | Tablet and pestles therefor | |
CA1201923A (en) | Acesulfam-containing compositions, tablets on the basis thereof and process for the manufacture of these tablets | |
CN103554000A (zh) | (s)-奥拉西坦晶型iii及其制备方法和用途 | |
WO2022228363A1 (zh) | 一种组合物的医药用途 | |
CN107693494B (zh) | 一种孟鲁司特钠颗粒组合物及其制备方法 | |
WO2014175303A1 (ja) | レボノルゲストレルの結晶多形α及びその製造方法 | |
WO2006090263A1 (en) | Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions | |
CN102988323A (zh) | 一种茴拉西坦缓释片的制备方法 | |
EP3073996A1 (en) | Pharmaceutical composition comprising amorphous ivabradine | |
JP3755908B2 (ja) | セファロスポリン化合物の晶析法 | |
JPS63119426A (ja) | 肝疾患治療薬組成物 | |
CN102796093B (zh) | 含硫代吗啉的吡咯衍生物、其制备方法和用途 | |
Gligor et al. | ASSESSMENT OF THE EFFECTS OF IBUPROFEN ASSOCIATION WITH NIFEDIPINE ON IBUPROFEN INDUCED HEPATOTOXICITY |